A randomized, double-blind, placebo-controlled study of benfluorex in hiv-infected patients with insulin resistance or impaired glucose tolerance

HIV Clinical Trials

Volumn 10, Issue 1, 2009, Pages 33-40

  Poizot Martin, I ^a   Drogoul Vey, M P ^a   Di Stefano, D ^b   Jouve, E ^c   Fabre, G ^a   Saout, A ^a   Gastaut, J A ^a  

^a HÔPITAL SAINTE MARGUERITE   (France)

^b INSTITUT PAOLI CALMETTES   (France)

^c TIMONE HOSPITAL   (France)

Author keywords

HIV lipodystrophy; Insulin resistance; Visceral fat mass

Indexed keywords

BENFLUOREX; FAT; INSULIN; LIPID; PLACEBO;

ABDOMINAL RADIOGRAPHY; ADULT; AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMPAIRED GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INTRAABDOMINAL FAT; LACTATE BLOOD LEVEL; LIPID BLOOD LEVEL; MALE; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SUBCUTANEOUS FAT;

EID: 64949197211     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/hct1001-33     Document Type: Article

References (26)

1. Despres JP, Lamarche B, Mauriege P, et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med. 1996;334:952-957.
2. Haffner SM, Mykkänen L, D'Agostino Jr R, et al. Insulin sensitivity in subjects with type 2 diabetes: Relationship to cardiovascular risk factors: The Insulin Resistance Atherosclerosis Study. Diabetes Care. 1999;22:562-568.
3. Cruz ML, Bergman RN, Goran MI. Unique effect of visceral fat on insulin sensitivity in obese Hispanic children with a family history of type 2 diabetes. Diabetes Care. 2002;25:1631-1636.
4. Poizot-Martin I, Marimoutou C, Di Stephano D, et al. Visceral fat-mass in 175 HAART-treated HIV-infected patients. Antiviral Ther. 2005;10:L22.
5. Knowler WC, Barett-Connor E, Fowler WE, et al. Reduction in the incidence of type 2 diabetes with lifetstyle intervention or metformin. N Engl J Med. 2002;346:393-403.
6. Hadigan C, Corcoran C, Basgoz N, Davis B, Sax P, Grinspoon S. Metformin in the treatment of HIV lipodystrophy syndrome: A randomized controlled trial. J Am Med Assoc. 2000;284:472-477.
7. Carr A, Workman C, Carey D, et al. No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: Randomised, doubleblind, placebo-controlled trial. Lancet. 2004;363:429-438.
8. Hadigan C, Yawetz S, Thomas A, Havers F, Sax PE, Grinspoon S. Metabolic effects of rosiglitazone in HIV lipodystrophy: A randomized, controlled trial. Ann Intern Med. 2004;140:786-794.
9. Sutinen J, Häkkinen AM, Westerbacka J, et al. Rosiglitazone in the treatment of HAART-associated lipodystrophy-a randomized double-blind placebo-controlled study. Antivir Ther. 2003;8:199-207.
10. Moyle GJ, Datta D, Mandalia S, Morlese J, Asboe D, Gazzard BG. Hyperlactataemia and lactic acidosis during antiretroviral therapy: Relevance, reproducibility and possible risk factors. AIDS. 2002;16:1341-1349.
11. van Wijk JP, de Koning EJ, Cabezas MC, et al. Comparison of rosiglitazone and metformin for treating HIV lipodystrophy: A randomized trial. Ann Intern Med. 2005;143: 337-346.
12. Derosa G, D'Angelo A, Ragonesi PD, et al. Metforminpioglitazone and metformin-rosiglitazone effects on nonconventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome. J Clin Pharm Ther. 2006;31:375-383.
13. Mulligan K, Yang Y, Wininger DA, et al. Effects of metformin and rosiglitazone in HIV-infected patients with hyperinsulinemia and elevated waist/hip ratio. AIDS. 2007;21: 47-57.
14. Broussole C, Coste M, Guilllon-Metz F, et al. Comparaison de l'action antidiabétique du benfluorex et de la metformine. Etude multicentrique. Sem Hôp Paris. 1988;64: 3153-3165.
15. Moulin P, Andre M, Alawi H, et al. Effi cacy of benfl uorex in combination with sulfonylurea in type 2 diabetic patients: An 18-week, randomized, double-blind study. Diabetes. 2006;29:515-520.
16. Del Prato S, Erkelens DW, Leutenegger M. Six-month efficacy of benfl uorex vs. placebo or metformin in diet-failed type 2 diabetic patients. Acta Diabetol. 2003;40:20-27.
17. Poizot-Martin I, Marimoutou C, Vion-Dury F, et al. Benfl uorex as a therapeutic option for insulin resistance in HIVlipodystrophy syndrome. HIV Clin Trials. 2004;5:86-90.
18. Lee A, Morley JE. Metformin decreases food consumption and induces weight loss in subjects with obesity with type II non-insulin-dependent diabetes. Obes Res. 1998;6:47-53.
19. Cigolini M, Targher G, Bergamo Andreis IA, Tonoli M, Agostino G, De Sandre G. Visceral fat accumulation and its relation to plasma hemostatic factors in healthy men. Arterioscler Thromb Vasc Biol. 1996;16:368-374.
20. Juhan-Vague I, Alessi MC, Morange PE. Hypofi brinolysis and increased PAI-1 are linked to atherothrombosis via insulin resistance and obesity. Ann Med. 2000;32(Suppl 1): 78-84.
21. He G, Andersen O, Haugaard SB, et al. Plasminogen activator inhibitor type 1 (PAI-1) in plasma and adipose tissue in HIV-associated lipodystrophy syndrome. Implications of adipokines. Eur J Clin Invest. 2005;35:583-590.
22. Hadigan C, Meigs JB, Rabe J, et al. Increased PAI-1 and tPA antigen levels are reduced with metformin therapy in HIV-infected patients with fat redistribution and insulin resistance. J Clin Endocrinol Metab. 2001;86:939-943.
23. Ribera RJ, Munoz CR, Ferrando AN, Sahun BN, Cels CA, Capamany PR. Valvular heart disease associated with benfl uorex. Rev Esp Cardiol. 2003;56:215-216.
24. Noize P, Sauer M, Bruneval P, et al. Valvular heart disease in a patient taking benfl uorex. Fundam Clin Pharmacol. 2006;20:577-578.
25. Sitbon O, Lascoux-lacombe C, Delfraissy JF, et al. Prevalence of HIV-related pulmonary arterial hypertension in the current antiretroviral therapy era. Am J Respir Crit Care Med. 2008;177:108-113.
26. Triant VA, Lee H, Hadigan C, Grinpoon SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodefi ciency virus disease. J Clin Endocrinol Metab. 2007;92:2506-2412.